Company Overview
Prenetics Global Limited operates as a consumer health sciences company in the United States and Hong Kong. The company focuses on advancing human health and longevity through science-backed products under the IM8 brand. It also operates a consumer genetic testing brand in CircleDNA leveraging sequencing technology to deliver personalized reports across various categories. The company was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Why Investors Should Care
Revenue has grown at a 91.5% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $92.39M (+479.8% YoY); net profit $-37.71M.
- Trailing 12 Months Year-on-year growth — revenue +210.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 91.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 91.46% |
| 1 Year: | 210.70% |
Stock Price Performance
| 1 Year: | +234.90% |
| 6 Months: | +25.04% |
| 3 Months: | +28.10% |
| 1 Month: | +40.31% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)67.49 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 91.5% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Defensive).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PRE Prenetics Global Limited | 25.62 | -7.40 | $389.38M | 0.00% | -21.50% | -47.01% | 91.46% | - |
| 2 | WMT Walmart Inc. SPXR3K | 107.14 | 38.82 | $850.02B | 0.93% | 16.83% | 22.31% | 3.82% | 3.24% |
| 3 | COST Costco Wholesale Corporation NDXSPXR3K | 910.18 | 45.88 | $403.65B | 0.65% | 25.96% | 29.15% | 8.16% | 11.45% |
| 4 | KO The Coca-Cola Company SPXR3K | 88.36 | 26.53 | $380.17B | 2.41% | 16.47% | 42.05% | 2.86% | 4.46% |
| 5 | PG The Procter & Gamble Company SPXR3K | 145.58 | 21.99 | $338.39B | 2.95% | 22.49% | 30.29% | 0.52% | 1.59% |
| 6 | PM Philip Morris International Inc. SPXR3K | 184.73 | 25.37 | $287.92B | 3.09% | 34.03% | -113.55% | -1.69% | 3.57% |
| 7 | PEP PepsiCo, Inc. NDXSPXR3K | 138.45 | 18.15 | $189.12B | 4.43% | 15.41% | 51.51% | 4.93% | 2.11% |
| 8 | BUD Anheuser-Busch InBev SA/NV | 79.73 | 17.18 | $139.30B | 1.69% | 8.49% | 11.39% | 0.88% | 4.63% |
| 9 | BTI British American Tobacco p.l.c. | 55.15 | 14.18 | $118.73B | 5.98% | 12.44% | 13.42% | -2.53% | 5.21% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 8.28M | 17.68M | 23.55M | 36.56M | 35.95M |
| Cost of Revenue | - | 2.67M | 10.39M | 9.53M | 14.97M | 12.67M |
| Gross Profit | - | 5.61M | 7.29M | 14.02M | 21.59M | 23.28M |
| Operating Expenses | - | 11.78M | 17.16M | 20.58M | 34.72M | 32.99M |
| Operating Income | - | -6.17M | -9.87M | -6.56M | -13.14M | -9.71M |
| EBITDA | - | -5.04M | -9.33M | -6.72M | -9.61M | -9.52M |
| Interest Expense | 78.63K | 69.00K | 65.00K | 55.00K | 45.00K | - |
| Pretax Income | - | -6.05M | -10.95M | -6.78M | -9.66M | -27.31M |
| Tax Provision | - | 20.00K | -33.00K | 9.00K | 38.00K | 28.00K |
| Net Income | - | -10.39M | -12.41M | -7.41M | -7.50M | -23.10M |
| Diluted EPS | - | -0.80 | -0.94 | -0.53 | - | -1.36 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 13.16M | 6.16M | 15.94M | 92.39M |
| Cost of Revenue | - | 9.55M | 4.98M | 6.66M | 43.60M |
| Gross Profit | - | 3.62M | 1.17M | 9.28M | 48.79M |
| Operating Expenses | - | 69.53M | 43.64M | 47.55M | 86.92M |
| Operating Income | - | -65.92M | -42.47M | -38.28M | -38.13M |
| EBITDA | - | -218.04M | -35.10M | -39.93M | -32.19M |
| Interest Expense | - | 242.00K | 46.00K | 168.00K | 241.00K |
| Pretax Income | - | -225.82M | -42.94M | -46.02M | -36.21M |
| Tax Provision | - | -245.00K | 54.00K | -7.64M | 34.00K |
| Net Income | - | -190.45M | -62.72M | -46.30M | -37.71M |
| Diluted EPS | - | -37.50 | -5.58 | -3.71 | -4.15 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 312.13M | 254.17M | 213.57M | 206.07M |
| Current Assets | - | 241.81M | 93.66M | 86.15M | 85.20M |
| Cash & Equivalents | - | 146.66M | 45.71M | 52.25M | 32.13M |
| Inventory | - | 4.53M | 3.13M | 6.57M | 7.03M |
| Receivables | - | 41.69M | 4.06M | 5.24M | 2.98M |
| Total Liabilities | - | 68.67M | 44.01M | 42.23M | 49.71M |
| Current Liabilities | - | 57.20M | 39.48M | 36.55M | 28.71M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 6.65M | 2.37M | 5.77M | 1.77M |
| Total Equity | - | 237.06M | 206.36M | 170.39M | 156.46M |
| Shares Outstanding | - | 9.13M | 12.22M | 12.98M | 16.87M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 14.52M | -13.77M | -28.87M | -21.83M |
| Investing Cash Flow | - | -46.15M | -82.95M | 38.54M | -35.69M |
| Financing Cash Flow | - | 143.32M | -4.70M | -3.34M | 37.47M |
| Capital Expenditure | - | -6.34M | -912.00K | -1.06M | -54.56M |
| Free Cash Flow | - | 8.17M | -14.68M | -29.94M | -76.39M |
| Net Change in Cash | - | 111.69M | -101.42M | 6.32M | -20.05M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 27.5% | 19.1% | 58.2% | 52.8% |
| Operating Margin % | - | -500.7% | -690.0% | -240.2% | -41.3% |
| Net Margin % | - | -1,446.8% | -1,019.1% | -290.6% | -40.8% |
| ROE % | - | -80.3% | -30.4% | -27.2% | -24.1% |
| ROCE % | - | -25.9% | -19.8% | -21.6% | -21.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Prospect Capital Advisors, LLC | 1.54% | 235.80K | $5.70M |
| 2 | Jane Street Group, LLC | 1.47% | 225.09K | $5.44M |
| 3 | Goldman Sachs Group Inc | 1.10% | 168.73K | $4.08M |
| 4 | Millennium Management Llc | 0.82% | 126.09K | $3.05M |
| 5 | Tenzing Global Management, Llc | 0.82% | 125.00K | $3.02M |
| 6 | Marshall Wace LLP | 0.31% | 47.33K | $1.14M |
| 7 | Nomura Holdings Inc. | 0.28% | 42.10K | $1.02M |
| 8 | Susquehanna International Group, LLP | 0.25% | 38.13K | $922.27K |
| 9 | UBS Group AG | 0.24% | 37.04K | $896.00K |
| 10 | Xtx Topco Ltd | 0.20% | 30.48K | $737.43K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PRE
FICO Stock Falls Pre-Market After Bill Pulte Declares ‘No More’ to FICO’s Mortgage Scoring Monopoly — Orders Fannie Mae, Freddie Mac to Open Door to VantageScore (UPDATED) - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxPcERpVTIweG1nQzkyNnI0bzhjNHRlN0xCRTh2U1dtU3UtWk1QUjRacjhNZlJ6TWVYaGhOZWQzUEFyOWJoU3A5aWRocjlGOHZRbGRYdU5sUXN3aWlsNHRYNUZTbkVJSm9XVVNXc3VnWktNWVRnWTBXYUtCa3pqODh6a0pPQzJsd0NRckNzcH…
Why Is ROIV Stock Tracking Record Highs In Pre-Market Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOeC1YaVRrNEg4LXlsS2UzMHRRQnhVWWtvZzFrWFpzblQ0cTVWdG1QWUY2bFNIRkJhRHNMc09ZQ2p3VDhCU25rMWptWVhISUxmSEVkbnZ4eGQyMG9ZVnRya1VOby1EcTV2ZENwamNNc0NoNGxDa1lvWGNPdzB1UjAxa3dxMUEzUmk5NnNROX…
Lululemon shares plunge, hit pre-COVID lows - CNBC
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPeEM3ZDFubWoyMGJITFZwUm9YbzB6d25QYTlBYnpzZWxPWXhjWjgtT3YxcGZLZFppeE9nVlNGNXpPMURBLVFteXpUOWRCbHpFYTVvUk5KelgzMnRmWjFFaEhpR282YmM4aGdXMlBfdU5TektzUi1rdDcxR3FweXNhdnI5eXlEaTRLT09GZW…
Intel Stock Tops $100 Pre-Market as High-NA EUV Enters Mass Production, Trump Posts INTC Stock Chart Again - TradingKey
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNZ09qYTBvUW53RS12OUFtSWRjeFZfRDh3RFMyNDNCWVNHazFpRFNhT1N2MDNvY0tfWmxCOVRqMmpPOWhQZnFTczlTbElyZ0hUd24zYzVYX01rakRibkpWSTVfVDFuaUVXcnpwOW5OU2FIUDZROGFOOFJBY1hKRk84cC1xWlR6aEtlRkFwWU…
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxNd1djQkZxUk5qbUQyQkRONmZyMzhLc1dtX3Q3ZXlCVm9iOEJ1U0NrYllnaDhKUk01Q1FjeFhvTTNCam1fRi1BR0RVUDZFU1IzeVZYenhUY0N5ajVTak9tQzAxTzVnSGk2b1pHRVJLd2lDUW81V1paMGVZNHdNSnV1bG9PM3ZFUHJhdnhkdl…
Prenetics (PRE) director receives 2,000 shares at $0.00, with 18,003 RSUs still outstanding - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQQ2JNZnlITlZXU193ZFpnZ1NPRjRfYkVVb3Ntb3FNRkF0UjdqaUJJVnRYOVZVWmZOZ2dIdmp0cDByNDhLS0d3aU15UWdoRlBHTGowWDc1Q2FsVjhHN1VnRGxsRjlxTnhlZkRSakFPMkp2NG83VGVhUkNFM1o0VldEd1VvdFUyemdyODI2T0…
PRE — Frequently Asked Questions
What is the current share price of Prenetics Global Limited (PRE)?
As of 2026-09-19 21:16 PDT, Prenetics Global Limited (PRE) trades at $25.62 on NasdaqGM. Its 52-week range is $7.25 to $26.25.
What is the market capitalisation of PRE?
Prenetics Global Limited (PRE) has a market capitalisation of $389.38M on NasdaqGM.
What is the P/E ratio of PRE?
PRE trades at a trailing price-to-earnings (P/E) ratio of -7.40. The industry average P/E is 18.56. Its price-to-book (P/B) ratio is 4.49.
What is the return on equity (ROE) of PRE?
PRE has a return on equity (ROE) of -47.01%. Its return on capital employed (ROCE) is -21.50%.
Is PRE a good stock to buy?
This page provides a data-driven analysis of Prenetics Global Limited (PRE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.